Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-07-29), Strides Pharma Science's 1-Year Sharpe Ratio is 0.65.
Strides Pharma Science (NSE:STAR) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Strides Pharma Science 1-Year Sharpe Ratio Related Terms
NSE:STAR vs ZTS: 1-Year Sharpe Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Strides Pharma Science's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strides Pharma Science 1-Year Sharpe Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Strides Pharma Science's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Strides Pharma Science's 1-Year Sharpe Ratio falls into.
Strides Pharma Science 1-Year Sharpe Ratio Calculation
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Strides Pharma Science (NSE:STAR) has a 1-Year Sharpe Ratio of 0.65 as of Jul. 29, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Strides Pharma Science and its competitors.
Is Strides Pharma Science's 1-Year Sharpe Ratio too high?
Strides Pharma Science's current 1-Year Sharpe Ratio is 0.65. Overall, Strides Pharma Science has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strides Pharma Science's 1-Year Sharpe Ratio compare to ZTS?
Strides Pharma Science's 1-Year Sharpe Ratio of 0.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Drug Manufacturers company?
A good 1-Year Sharpe Ratio depends on the Drug Manufacturers industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Strides Pharma Science and its competitors. Strides Pharma Science's current 1-Year Sharpe Ratio is 0.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strides Pharma Science stock overvalued right now?
Based on GuruFocus' analysis, Strides Pharma Science (NSE:STAR) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹762.73, compared to a current price of ₹1,060.00 — trading 39% above its estimated fair value. The current 1-Year Sharpe Ratio is 0.65. Strides Pharma Science's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Strides Pharma Science (NSE:STAR), the current 1-Year Sharpe Ratio is 0.65 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strides Pharma Science (NSE:STAR) Overvalued in 2026?
Based on GuruFocus' analysis, Strides Pharma Science stock appears to be overvalued.
The current stock price of ₹1,060.00 is trading 39% above its estimated GF Value™ of ₹762.73.
GuruFocus considers Strides Pharma Science to be Significantly Overvalued.
Key valuation signals for NSE:STAR:
1-Year Sharpe Ratio: 0.65
GF Value™: ₹762.73 vs. price of ₹1,060.00 (39% above fair value)
No single metric tells the full story. See the NSE:STAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strides Pharma Science Ltd develops and manufactures a wide range of IP-led niche pharmaceutical products. Its diverse portfolio spans complex generics across multiple dosage forms, including tablets, hard capsules, sachets, liquids, nasal sprays, topicals, and controlled substances. It also manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, Hepatitis, and other infectious disease drug segments for its institutional business. The customers for this business include institutionally funded aid projects and procurement agencies. With its R&D, integration, and distribution network, the company brings differentiated products to market across the U.S., Australia, Europe, Africa, and Emerging Markets. Geographically, it generates maximum revenue from North America.
65GF Score
Get the complete analysis for NSE:STAR
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:STAR has been successfully added to your 
